Thrombolex Inc.

Founded in 2016, Thrombolex, Inc. is engaged in the design, development, manufacture and distribution of innovative endovascular catheters.

02/22/2026

The BASHIR™ Endovascular Device is designed for efficient placement, controlled mechanical fragmentation and targeted delivery of thrombolytics for the treatment of pulmonary embolism. Its 0.035"" guidewire compatibility supports procedural ease and speed while enabling on-the-table pharmaco-mechanical lysis (PML).

Thrombolex.com

02/20/2026

The RAPID-PE Study is a post-market, single-arm, multicenter study investigating on-the-table PML without post-procedural thrombolytic infusion using the BASHIR™ Endovascular Device. Interim results have shown that the approach can efficiently restore blood flow, eliminate ICU stays, and support safe recovery.

These findings emphasize Thrombolex’s commitment to real-world evidence, clinical confidence, and patient-centered therapies.

https://thrombolex.com/interim-data-from-the-rapid-pe-study-presented-at-tct-2025/

02/18/2026

Pulmonary Embolism remains a leading cause of preventable in-hospital mortality. Pharmaco-mechanical lysis (PML) is controlled mechanical fragmentation and targeted thrombolytics, this can restore blood flow quickly and reduce the burden on patients and providers.

At Thrombolex, our focus is on solutions that help clinicians deliver single-session treatment and improve patient outcomes.

02/16/2026

Effective PE treatment requires more than thrombolytics alone. By integrating mechanical action with targeted delivery, BASHIR™ Endovascular Devices enable controlled clot fragmentation while limiting thrombolytic exposure to where it is needed most.

Thrombolex.com

02/14/2026

The ongoing RAPID-PE Study demonstrates real-world safety and effectiveness in treating intermediate-risk pulmonary embolism. Using on-the-table pharmaco-mechanical lysis with the BASHIR™ Endovascular Device, interim data shows efficient blood flow restoration and low ICU utilization, supporting faster recovery and improved patient outcomes.

Thrombolex.com

02/12/2026

The BASHIR™ Endovascular Device is designed to support efficient, controlled treatment of pulmonary embolism. By combining mechanical clot fragmentation with targeted thrombolytic delivery, the device helps simplify procedural workflows while supporting safe and effective on-the-table pharmaco-mechanical lysis (PML).

Thrombolex.com

02/11/2026

Thank you to the iSET Conference team for an outstanding event, and to everyone who connected with us at iSET 2026. To learn more about Thrombolex's novel portfolio of Endovascular Devices, visit Thrombolex.com

01/19/2026

Today, we reflect on the enduring impact of Dr. Martin Luther King Jr. His commitment to service and humanity continues to inspire progress and purpose within our communities.

Thrombolex.com

01/13/2026

The BASHIR™ S-B Endovascular Catheter features a shorter infusion basket for smaller vessels, enabling precise thrombolytic infusion tailored to each patient’s anatomy. Designed for flexibility and control, it supports targeted therapy with procedural efficiency.

Thrombolex.com

01/01/2026

Happy New Year from Thrombolex.

Thrombolex.com

12/30/2025

Dr Barry Bertolet discusses that, with an intuitive design and minimal learning curve, the BASHIR™ Endovascular Catheter makes PE treatment straightforward, empowering more physicians to deliver life-saving care quickly and confidently.

Thrombolex.com

12/26/2025

To all who celebrate, Thrombolex wishes you a Happy Kwanzaa.

Thrombolex.com

Address

75 Britain Drive
New Britain, PA
18901

Telephone

+18447926300

Website

http://www.thrombolex.com/

Alerts

Be the first to know and let us send you an email when Thrombolex Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Thrombolex Inc.:

Shortcuts

Want your practice to be the top-listed Clinic in New Britain?